Biomedical subjects

A Talavera

Publications and source records attributed to A Talavera.

60 records · Page 4Linked to original sources

PubMedDate not supplied

[Prognostic importance of beta-2-microglobulin in multiple myeloma].

Beta 2 microglobulin is a low molecular weight protein found on the surface of all nucleated cells: it is the light chain of the HL-A histocompatibility complex. The increased levels of serum beta 2 microglobulin in patients with multiple myeloma have been associated with a poor prognosis. Pretreatment levels of serum beta 2 microglobulin were estimated in 70 previously untreated patients with multiple myeloma. In a multivariate analysis, serum beta 2 microglobulin levels and stage were the most significant prognostic factors for survival independent of other risk factors associated with a worse prognosis. There was a clear difference in survival duration observed between the patients with a high pretreatment level of beta 2 microglobulin and stage III (none alive at 5 years) compared with patients with normal levels and stage I (80% alive at five years) (p less than .001). We conclude that pretreatment-beta 2 microglobulin level is one of the most useful prognostic factors in patients with multiple myeloma.

Actuarial Analysis↗

PubMedDate not supplied

[Preinduction in the treatment of patients with malignant lymphoma].

Prospective clinical study of ninety-eight patients with untreated malignant lymphoma were randomly assigned to be treated wether with combined chemotherapy: cyclophosphamide, hidroxidaunil adriamycin, vincristine, prednisone and bleomycin (CHOP-Bleo) or with two low-dose of methotrexate as preinduction regimen and the same chemotherapy: CHOP-Bleo. The number of early deaths afterwards the group was less with preinduction, also more of them had complete remission, it lasted longer and survival was better than in the group just treated with conventional chemotherapy. Toxicity, secondary to preinduction chemotherapy. Toxicity, secondary to preinduction regimen was acceptable, while it was similar in both groups receiving conventional chemotherapy. Supported on these results it is considered that the use of preinduction regimen, as herein described, is useful in patients with malignant lymphoma and should be applied for the therapeutic approach of these neoplasms.

Antineoplastic Combined Chemotherapy Protocols↗

PubMedDate not supplied

[Comparative study of high doses vs conventional doses of cytosine arabinoside combined with cisplatin and dexamethasone in patients with refractory lymphoma].

Forty-three patients with advanced malignant lymphoma resistant to previous chemotherapy were randomized in two groups: one received a high dose versus a low-dose cytosine arabinoside, in combination with dexamethasone and cisplatinum. Ten of 24 patients (41%) in the low-dose regimen achieved response: six complete remission (CR) and four partial remission (PR), compared with 5 of 19 (30%) (three CR and two PR). Survival was better in the low dose regimen: 39 versus 23 weeks. Toxicity was most frequent and severe in the high dose schedule. These results suggests that the use of cytosine arabinoside and cisplatinum is useful in the treatment of refractory lymphoma, and that the low-dose would be a better alternative than a high dose.

Adult↗

PubMedDate not supplied

[Solitary plasmacytoma. A retrospective analysis of 15 cases].

Solitary plasmocytoma is a rare plasma cell disorder as compared with multiple myeloma. In order to evaluate their relationships, the clinical findings in 51 patients with solitary plasmocytoma were analyzed. The median follow-up was 7.8 years (range 3 to 14). Twenty patients (39%) developed multiple myeloma in a average of 3.8 years. The risk factors associated with the development of multiple myeloma were an initial abnormal electrophoresis (M peak), age (less than 40 years) and an increase in beta-2-microglobulin. Although radiotherapy remains the initial treatment of solitary plasmocytoma, a careful evaluation should be performed in order to consider chemotherapy in selected patients with high risk of developing multiple myeloma.

Actuarial Analysis↗

PubMedDate not supplied

[Alkaline phosphatase as a prognostic factor in Hodgkin's disease].

Serum alkaline phosphatase level have been studied in 102 patients a the onset of Hodgkin's disease who were staged by laparotomy. Elevated phosphatase was observed in 34 cases who had a worse relapse free survival (RFS): 63 months versus 93 months in patients with normal level (p less than 0.001). Also, overall survival was affected by elevated phosphatase, because patients with this finding had a 10-year survival of 42 percent compared with 70 percent of patients with normal level. We felt that patients with elevated serum alkaline phosphatase should be considered in advanced stage, even other studies remain normal and therapeutic options would considered the use of chemotherapy.

Adolescent↗

PubMedDate not supplied

[Granulocyte-macrophage colony-stimulating factor in the treatment of secondary bone marrow suppression in patients with lymphoma. Preliminary report].

Four patients with severe myelosuppression secondary to chemotherapy for advanced malignant lymphoma were treated with human granulocyte macrophage colony-stimulating factor (GM-CSF) at dose of 10 micrograms/kg/day. The number of absolute granulocytes increase in all patients in the first 3 days after the treatment was begun. Normal values were observed after 5 days on treatment. No toxicities resulted from the treatment. The results demonstrate the utility of GC-CSF in restoring normal granulocytes counts in patients undergoing intensive chemotherapy.

Adult↗